Background: Regular examinations of oral health allow dentists clinical assessment of the state of dentition and oral soft tissues in patients, early diagnosis and treatment of the diagnosed disease entity, identification of risk factors of oral diseases as well as prophylaxis and pro-health education. Aim of the study was analysis of the frequency of oral health examination in the group of people in aged 20-54 with considering sociodemographic data and the status of cigarette smoking.
Materials And Methods: Sociomedical examinations were conducted in the group of 124 people in the age of 20-54. In order to assess the status of cigarette smoking cotinine concentration in non-stimulated saliva was assayed with the use of Cotinine test (Calbiotech, USA). Statistic analysis of the obtained results was performed with the use of Chi2 and Kruskal-Wallis tests. Test values considered to be statistically significant were those of p<0.05.
Results: 32.76% smokers and 9.09% non-smokers had their dental appointment less frequently than once a year to have their oral health examined, whereas regular dental check-ups every six months were declared by 43.10% and 56.06% and once a year 24.14% and 34.85% respectively. In the group of smokers no correlation was stated between the frequency of their dental check-ups and their age (H=1.12, p>0.05), sex (chi2=0.09, p>0.05) and place of residence (chi2=1.66, p>0.05). In the group of non-smokers no correlations were stated between the age (H=4.39, p>0.05), sex (chi2=1.01, p>0.05), place of residence (chi2=2.40, p>0.05) and the frequency of oral health check-ups. Non smokers have their dental check-ups every six months essentially more frequently than smokers (chi2 = 10.80, p<0.01).
Conclusions: Age, sex, place of residence do not influence the frequency of oral health examinations among people in the aged 20-54. Non smokers have their dental check-ups every six months essentially more frequently than smokers.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association of socio-demographic characteristics, comorbidities, lifestyle habits, and saliva parameters with dental caries in adults with obesity.
Acta Odontol Scand
January 2025
CHU de Bordeaux, Pôle de Médecine et Chirurgie Bucco-Dentaire, F-33000 Bordeaux, France; Univ. Bordeaux, Oral Health Department, F-33000 Bordeaux, France.
Objective: To describe the oral health status of patients with obesity and to explore the socio-demographic characteristics, comorbidities, lifestyle habits (tobacco, alcohol, sweet/acidic diet), and saliva parameters most associated with the dental caries experience. Material and methods: We conducted a cross-sectional analysis of 204 patients' data with obesity attending a therapeutic education programme. Caries experience (number of decayed, missing, and filled teeth [DMFT]), periodontal status, oral hygiene, occlusal tooth wear, masticatory inefficiency, and saliva parameters were recorded.
View Article and Find Full Text PDFThis study aimed to gain knowledge of general oral health preventive measures with a specific focus on root caries preventive measures for patients ≥65 years old, performed by Norwegian dental hygienists in public and private dental health services. A secondary aim was to investigate differences and challenges in prevention practices. Materials and methods: An electronic survey was conducted among the sample in 2022.
View Article and Find Full Text PDFAn Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.
JAMA Neurol
January 2025
Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.
Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.
Design, Setting, And Participants: This phase 2 randomized double-blind placebo-controlled crossover clinical trial was conducted from October 21, 2020, to February 27, 2023, at 19 sites in the US.
Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial.
JAMA
January 2025
Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.
Importance: Metformin and glyburide monotherapy are used as alternatives to insulin in managing gestational diabetes. Whether a sequential strategy of these oral agents results in noninferior perinatal outcomes compared with insulin alone is unknown.
Objective: To test whether a treatment strategy of oral glucose-lowering agents is noninferior to insulin for prevention of large-for-gestational-age infants.
Background: Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2-11 years with mild to moderate atopic dermatitis (AD).
Objective: This study examined the safety, tolerability, pharmacokinetics, efficacy, and quality of life (QoL) with ruxolitinib cream under maximum-use conditions and with longer-term use.
Methods: Eligible patients were aged 2-11 years with moderate to severe AD [Investigator's Global Assessment (IGA) score 3-4], and ≥ 35% affected body surface area (BSA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!